Brentuximab vedotin significantly improves progression free survival in hard-to-treat Hodgkin lymphoma
by Bruce Sylvester: Researchers from a phase 3, randomized trial of brentuximab vedotin report that adults with hard-to-treat Hodgkin lymphoma treated with brentuximab vedotin immediately after stem cell… read more.